This study, alongside more than 100 other peer-reviewed papers, confirms the link between mRNA injections and deadly cancer pathways. A new medical term has even been coined: COVID-19 Vaccine-Induced “Turbo Cancer.”
More from Focal Points:
THE FIRST FORMAL SIGNAL: INCREASED CANCER RISK
Despite strong “healthy vaccinee bias” (explained below), the study still found multiple increases in cancer hospitalizations among vaccinated individuals.
Overall cancer risk:
- +23% increased risk after ≥1 dose (HR 1.23, 95% CI 1.11–1.37) (statistically significant)
- +9% increased risk after ≥3 doses (HR 1.09, 95% CI 1.02–1.16) (statistically significant)
BY CANCER SITE (Hazard Ratios Converted to % Increased Risk)
Breast cancer
- +54% with ≥1 dose (HR 1.54, 95% CI 1.10–2.16) (statistically significant)
- +36% with ≥3 doses (HR 1.36, 95% CI 1.08–1.72) (statistically significant)
Bladder cancer
- +62% with ≥1 dose (HR 1.62, 95% CI 1.07–2.45) (statistically significant)
- +43% with ≥3 doses (HR 1.43, 95% CI 1.08–1.88) (statistically significant)
Colon-rectum cancer
- +35% with ≥1 dose (HR 1.35, 95% CI 1.01–1.80) (statistically significant)
- +14% with ≥3 doses (HR 1.14, 95% CI 0.96–1.36) (not statistically significant)
Hematological cancers (leukemia/lymphoma)
- +31% with ≥1 dose (HR 1.31, 95% CI 0.96–1.79) (not statistically significant)
- +7% with ≥3 doses (HR 1.07, 95% CI 0.89–1.29) (not statistically significant)
Uterine cancer
- +77% with ≥1 dose (HR 1.77, 95% CI 0.76–4.13) (not statistically significant)
- +20% with ≥3 doses (HR 1.20, 95% CI 0.73–1.96) (not statistically significant)
Ovarian cancer
- +71% with ≥1 dose (HR 1.71, 95% CI 0.60–4.82) (not statistically significant)
- +86% with ≥3 doses (HR 1.86, 95% CI 0.68–5.12) (not statistically significant)
Thyroid cancer
- +58% with ≥1 dose (HR 1.58, 95% CI 0.84–2.99) (not statistically significant)
- -3% with ≥3 doses (HR 0.97, 95% CI 0.67–1.45) (not statistically significant)
Prostate cancer
- +1% with ≥1 dose (HR 1.01, 95% CI 0.68–1.49) (not statistically significant)
- -3% with ≥3 doses (HR 0.97, 95% CI 0.76–1.23) (not statistically significant)
Lung cancer
- -10% with ≥1 dose (HR 0.90, 95% CI 0.68–1.18) (not statistically significant)
- -7% with ≥3 doses (HR 0.93, 95% CI 0.79–1.11) (not statistically significant)
WHAT THIS MEANS
- The strongest, statistically significant increases were found for breast, bladder, colorectal, and overall cancer risk.
- Nearly all other cancer sites also showed an upward trend, though not statistically significant due to wide confidence intervals.
- Only lung and prostate cancers showed no evidence of increased risk.
This pattern suggests a real signal that is partially obscured by confounders and limited follow-up time.